A Phase 2 interventional study of TVB-2640 25 mg (US) and TVB-2640 50 mg (US) in MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis), sponsored by Sagimet Biosciences Inc.. Completed at 23 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-19.
Sponsored by Sagimet Biosciences Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.
Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 114th largest by enrollment of the 460 interventional ones that give a count, is one of 62 that started in 2019, is one of 192 in phase 2, and was the 286th registered.
1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 323 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
Regeneron Pharmaceuticals · Sites in United States, Puerto Rico, United Kingdom
Ages 18–75
Columbia University · Sites in United States
Ages 18–65
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
GlaxoSmithKline · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 220 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 125 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
547 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 93 · Phase 2 213 · Phase 3 36 · Phase 4 13
First in 2000; this study’s year is marked. 62 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 142 is above the median of 60 across 1,177 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 56 across the 460 interventional studies, 90 across the 85 observational. Of the 420 that completed or were terminated, 216 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
246 of 547 have an industry lead sponsor. The 10 most frequent:
Sagimet Biosciences Inc. is the lead sponsor of 10 studies on the registry; 2 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.
Sagimet Biosciences Inc. has 5 studies filed under Non-alcoholic Fatty Liver Disease — fewer than ten, so there is no comparison to draw.
22 of the studies in Non-alcoholic Fatty Liver Disease with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04951219Phase 3Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | 2027-03 |
| NCT04833140Phase 3Massachusetts General HospitalEstrogen Administration for the Treatment of NASH in Postmenopausal Women | 2027-07-09 |
| NCT00983463Vanderbilt UniversityAbundance and Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD) | 2026-11 |
| NCT05165706Stanford UniversityLongitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance | 2026-11-30 |
| NCT05067621Yale UniversitySemaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease | 2026-12 |
Add all 22 to your calendar (.ics) → With an account.
Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2 multi-center, randomized, single-blind, placebo-controlled study to evaluate the safety and efficacy of TVB-2640 in subjects with non-alcoholic steatohepatitis (NASH), a type of fatty liver disease. Subjects will be randomly assigned to 1 of 2 treatment groups (TVB-2640 at one of three doses or placebo). Following randomization, subjects will begin the 12-week treatment period and will receive once daily TVB-2640 or placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Prior liver within 24 months of randomization with fibrosis Stage 1 to 3 and a non-alcoholic fatty liver disease (NAFLD) activity score (NAS) of ≥ 4 with at least a score of 1 in each of the following NAS components:
AND
OR, if prior biopsy is not available:
AND
Exclusion Criteria:
Subjects meeting any of the following criteria are not eligible for enrollment in the study.
History of significant alcohol consumption for a period of more than 3 consecutive months within 1 year prior to screening.
Note: Significant alcohol consumption is defined as average of > 20 g/day in female subjects and > 30 g/day in male subjects.
Uncontrolled Type 2 diabetes defined as:
Note: Individual diabetes regimens will be reviewed by Investigator and may be adjusted based on American Diabetes Association guidelines.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects randomly assigned to receive the study drug will take TVB-2640 tablet orally every day for 12 week treatment period. The dose is to be taken at the same time of the day, with each dose separated by 24 hours (±4 hours).
Drug: TVB-2640 25 mg (US)
Subjects randomly assigned to receive the study drug will take TVB-2640 tablet orally every day for 12 week treatment period. The dose is to be taken at the same time of the day, with each dose separated by 24 hours (±4 hours).
Drug: TVB-2640 50 mg (US)
Subjects randomly assigned to placebo will receive placebo tablets orally once a day under the same conditions and frequency as described for TVB-2640.
Drug: Placebo (US)
Subjects randomly assigned to receive the study drug will take TVB-2640 tablet orally every day for 12 week treatment period. The dose is to be taken at the same time of the day, with each dose separated by 24 hours (±4 hours).
Drug: TVB-2640 50 mg (China)
Subjects randomly assigned to placebo will receive placebo tablets orally once a day under the same conditions and frequency as described for TVB-2640.
Drug: Placebo (China)
After completion of Cohorts 1 and 2, and if no stopping criteria are met upon review by the Independent SRC, an additional TVB-2640 75 mg open-label Cohort 3 will open in the US
Drug: TVB-2640 75 mg (US)
Oral dose, tablet, daily dosing
Oral dose, tablet, daily dosing
Oral dose, tablet, daily dosing
Oral dose, tablet, daily dosing
Oral dose, tablet, daily dosing
Oral dose, tablet, daily dosing
Percent Change in Hepatic Fat Fraction by Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) From Baseline
As determined by MRI-PDFF
Time frame: 12 weeks
Percentage of Subjects With at Least a 30% Reduction in Liver Fat at Week 12.
As determined by MRI-PDFF
Time frame: 12 weeks
Percentage of Change From Baseline in Alanine Aminotransferase (ALT)
Time frame: 12 weeks
| Milestone | TVB-2640 25 mg (US) | TVB-2640 50 mg (US) | Placebo (US) | TVB-2640 50 mg (China) | Placebo (China) | TVB-2640 75 mg (US) |
|---|---|---|---|---|---|---|
| Started | 33 | 35 | 31 | 21 | 9 | 13 |
| Completed | 27 | 30 | 31 | 20 | 9 | 11 |
| Not completed | 6 | 5 | 0 | 1 | 0 | 2 |
As determined by MRI-PDFF
| percent change from baseline | TVB-2640 25 mg (US) | TVB-2640 50 mg (US) | Placebo (US) | TVB-2640 50 mg (China) | Placebo (China) | TVB-2640 75 mg (US) |
|---|---|---|---|---|---|---|
| Percent Change in Hepatic Fat Fraction by Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) From Baseline | -11.31 ± 29.837 | -27.59 ± 28.354 | 2.52 ± 33.030 | -28.68 ± 22.265 | -15.63 ± 30.789 | -35.77 ± 23.736 |
As determined by MRI-PDFF
| Participants | TVB-2640 25 mg (US) | TVB-2640 50 mg (US) | Placebo (US) | TVB-2640 50 mg (China) | Placebo (China) | TVB-2640 75 mg (US) |
|---|---|---|---|---|---|---|
| Percentage of Subjects With at Least a 30% Reduction in Liver Fat at Week 12. | 7 | 16 | 3 | 10 | 2 | 4 |
| percentage of change | TVB-2640 25 mg (US) | TVB-2640 50 mg (US) | Placebo (US) | TVB-2640 50 mg (China) | Placebo (China) | TVB-2640 75 mg (US) |
|---|---|---|---|---|---|---|
| Percentage of Change From Baseline in Alanine Aminotransferase (ALT) | -2.98 ± 38.443 | -20.46 ± 25.935 | 6.82 ± 37.258 | -28.29 ± 34.495 | 14.06 ± 79.621 | -3.296 ± 42.5397 |
Collected over 12 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TVB-2640 25 mg (US) | 0/33 (0%) | 0/33 (0%) | 25/33 (75.8%) |
| TVB-2640 50 mg (US) | 0/35 (0%) | 0/35 (0%) | 14/35 (40%) |
| Placebo (US) | 0/31 (0%) | 0/31 (0%) | 12/31 (38.7%) |
| TVB-2640 50 mg (China) | 0/21 (0%) | 0/21 (0%) | 17/21 (81%) |
| Placebo (China) | 0/9 (0%) | 0/9 (0%) | 5/9 (55.6%) |
| TVB-2640 75 mg (US) | 0/13 (0%) | 0/13 (0%) | 9/13 (69.2%) |
| Event | TVB-2640 25 mg (US) | TVB-2640 50 mg (US) | Placebo (US) | TVB-2640 50 mg (China) | Placebo (China) | TVB-2640 75 mg (US) |
|---|---|---|---|---|---|---|
| Dry EyeEye disorders | 1/33 | 1/35 | 1/31 | 8/21 | 2/9 | 5/13 |
| Skin exfoliationSkin and subcutaneous tissue disorders | 0/33 | 0/35 | 0/31 | 7/21 | 0/9 | 0/13 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 0/33 | 0/35 | 0/31 | 3/21 | 0/9 | 3/13 |
| Diffuse alopeciaSkin and subcutaneous tissue disorders | 0/33 | 0/35 | 0/31 | 0/21 | 0/9 | 3/13 |
| HeadacheNervous system disorders | 4/33 | 2/35 | 2/31 | 0/21 | 0/9 | 2/13 |
| Abdominal distensionGastrointestinal disorders | 2/33 | 0/35 | 1/31 | 0/21 | 0/9 | 2/13 |
| ConstipationGastrointestinal disorders | 1/33 | 1/35 | 1/31 | 0/21 | 0/9 | 2/13 |
| Upper respiratory tract infectionInfections and infestations | 2/33 | 2/35 | 1/31 | 3/21 | 1/9 | 0/13 |
| AsthenopiaEye disorders | 0/33 | 0/35 | 0/31 | 0/21 | 1/9 | 0/13 |
| Conjunctival depositEye disorders | 0/33 | 0/35 | 0/31 | 0/21 | 1/9 | 0/13 |
The overall number of participants that are provided here are as per safety population. Note- The Safety Population consisted of all randomized subjects who received at least 1 dose of study drug. Analysis is based on randomized treatment group.
| Age, Categorical(Participants) | TVB-2640 25 mg (US) | TVB-2640 50 mg (US) | Placebo (US) | TVB-2640 50 mg (China) | Placebo (China) | TVB-2640 75 mg (US) | Total |
|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 27 | 29 | 27 | 19 | 8 | 12 | 122 |
| >=65 years | 6 | 6 | 4 | 2 | 1 | 1 | 20 |
| Sex: Female, Male(Participants) | TVB-2640 25 mg (US) | TVB-2640 50 mg (US) | Placebo (US) | TVB-2640 50 mg (China) | Placebo (China) | TVB-2640 75 mg (US) | Total |
|---|---|---|---|---|---|---|---|
| Female | 15 | 13 | 17 | 4 | 3 | 5 | 57 |
| Male | 18 | 22 | 14 | 17 | 6 | 8 | 85 |
| Ethnicity (NIH/OMB)(Participants) | TVB-2640 25 mg (US) | TVB-2640 50 mg (US) | Placebo (US) | TVB-2640 50 mg (China) | Placebo (China) | TVB-2640 75 mg (US) | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 22 | 24 | 25 | 0 | 0 | 13 | 84 |
| Not Hispanic or Latino | 11 | 11 | 6 | 21 | 9 | 0 | 58 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | TVB-2640 25 mg (US) | TVB-2640 50 mg (US) | Placebo (US) | TVB-2640 50 mg (China) | Placebo (China) | TVB-2640 75 mg (US) | Total |
|---|---|---|---|---|---|---|---|
| United States | 33 | 35 | 31 | 0 | 0 | 13 | 112 |
| China | 0 | 0 | 0 | 21 | 9 | 0 | 30 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2019 to primary completion in Oct 2021, 30 months.
Results were first posted in Dec 2024, 3 years 2 months after primary completion.
Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 30 months is above that.
Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TVB-2640
Non-alcoholic Fatty Liver Disease →
Sagimet Biosciences Inc.